Sapan Gai, CCO at Sovereign Metals, discusses their superior graphite test results. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
All this with just 12 employees. Pretty good and congratulations for what they have achieved with such a small group.
USA have to wait until 2025.
Reading the 2.2 notes doesn't sound too promising.
Can't see the share price going anywhere for a while. Sold out this morning, I don't hold many shares but too long term for me now. They have potential of massive market but with everyone else doing the work cash flow won't be coming in steadily and milestone payments may not be enough or delayed as they say in these notes. Will keep an eye on the share in future.
Good luck to everyone here though. Keep hard👍
There's nothing new in this RNS. What the heck are they playing at? Unbelievable. Can see this tracing back hard this month
There are no news in the results as all were announced before. Expecting to see how the 1st quarter progressing and hence price drop
Big results really come in 2024 and a big uplift in 2025. Good long term hold with the share price rising as a good income stream comes in and more than likely dividends.
Hi, these R&D priority areas including female health product development points were all covered in an interview that was posted online a few months back. You will no doubt then ask where is it now - well it has been posted here at some point back and if no one can easily find it, I will see it I can find it later..
They stated the Haleon $4 million upfront will be recorded in this years revenues
I'm reading the RNS as profitability in FY2024 (this year) which was not on the balance sheet in previous years. Getting a feeling this will tick up
Plenty of positive intent thats for sure. Along with enthusiasm over being able to supply the ROW and USA.
I wont be around to listen to the investors presentation at 0900. Really appreciate anyone who can post some of the highlights.
Of course I'm happy to see finally some cash start to flow in but a couple of points I feel were missing from the RNS.
1. In future strategy it talks about commercialising other OTC products for the sexual health market. What could those be? A ladies' product? Back to gel in a durex? No idea from reading the text.
2. Absolutely NOTHING on non sexual health development, not a peep. What about local pain relief? That was our main thrust a while ago. There is a massive market coming from multidirections: sprains, minor sports injuries, arthritic joints, patients awaiting replacement joints, and many more.
I'm always concerned about the risks of investing in one trick ponies. At least I would hope we would make some of the right noises about future directions.
Think it's a pretty standard notice in most financial statements.
but I cannot find Note 2.2 of the Preliminary Results in previous rns's - anybody have an idea
Yes.Early 2025 launch for USA is mentioned and is a key piece of information. Nothing else much that is new in the RNS.
The bit about going concern is standard wording that has to be included and I would not be worried about that.
I seen it as early 2025 for USA launch. Trying to find it again so I can post.
Not sure I like this statement.
The Directors believe that it remains appropriate to prepare the financial statements on a going concern basis. However, they also acknowledge that a material uncertainty exists that may cast significant doubt on the Group's ability to generate sufficient net revenues and resulting cash inflows and raise sufficient finance to meet its expected costs to discharge its liabilities in the normal course of business. The financial statements do not include any adjustments that would result from the basis of preparation being inappropriate.
The auditor's report includes reference to the material uncertainty relating to going concern. Further information in relation to going concern can be found in Note 2.2 of the Preliminary Results
"further revenue growth and progress on the path towards profitability in the next 12 months"
The magic word
The Company delivered a gross margin of approximately 57%
I suspect a lot of detail is waiting on the presentation at 9am - so on that basis I have signed up to view this.
Copy and paste of the trading update which gave January orders of £.5m.
If Feb and March were better could have mentioned this.
Disappointed that it was a re hash of the trading update
See what the presentation brings
I wished they'd been a more specific about timings for the US release. But I guess that's up to Haleon...
Thats comforting.
Not bad considering we have many markets including the USA to open.
That is how I am reading it.
The Haleon upfront payment will be logged in the first half update (normally realsed in Sept)
"Eroxon® initially launched in March 2023 and the Company delivered total revenue of £3.10 million in 2023 (2022: nil). Revenues were predominantly generated from Eroxon® sales and further details of revenue are provided in Note 5 to the consolidated financial statements."
So £3.1 million in revenue not including the upfront payment. Is that what everyone else is reading?
Looks like some great news! Could be a nice lift in SP today
No new news as far as I can see
Very true.
Nice tick up today anyways, good to see a bit of green once in a while, red is such a depressing colour.
I was about to ask for these figures to be signposted.
The only performance indicator Ive read is 20% market share in the UK and Belgium. We still don’t know how many units sold and what cut we have of that. It’s been my reasoning why the SP is where it is.
Hoping doubts are put to bed as we get out of bed tomorrow.